Results 41 to 50 of about 35,241 (222)

Clinicogenomic analysis of FGFR2-rearranged cholangiocarcinoma identifies correlates of response and mechanisms of resistance to pemigatinib.

Cancer Discovery, 2020
Pemigatinib, a selective fibroblast growth factor receptor (FGFR) 1-3 inhibitor, has demonstrated antitumor activity in FIGHT-202, a phase 2 study in patients with cholangiocarcinoma harboring FGFR2 fusions/rearrangements, and has gained regulatory ...
I. Silverman, A. Hollebecque, L. Friboulet, S. Owens, R. Newton, H. Zhen, L. Féliz, C. Zecchetto, D. Melisi, T. Burn   +9 more
semanticscholar   +1 more source

FGFR2 alterations in endometrial carcinoma [PDF]

Modern Pathology, 2011
Fibroblast growth factor receptor 2 (FGFR2) is a tyrosine kinase receptor involved in many biological processes such as embryogenesis, adult tissue homeostasis and cell proliferation. Mutations in FGFR2 have been reported in up to 10-12% of endometrial carcinomas identical to those found in congenital craniofacial disorders.
Gatius, S, Velasco, A, Azueta, A, Santacana, M, Pallares, J, Valls, J, Dolcet, X, Prat, J, Matias-Guiu, X   +8 more
openaire   +3 more sources

Targeting FGFR2 Positive Gastroesophageal Cancer: Current and Clinical Developments

OncoTargets and Therapy, 2022
Despite recent advances in the systemic treatment of gastroesophageal cancers, prognosis remains poor. Comprehensive molecular analyses have characterized the genomic landscape of gastroesophageal cancer that has established therapeutic targets such as ...
Anderley Gordon, Edwina Johnston, David Lau, N. Starling   +3 more
semanticscholar   +1 more source

Serum IgG as a Marker for Opisthorchis viverrini-Associated Cholangiocarcinoma Correlated with HER2 Overexpression

International Journal of General Medicine, 2020
Attapol Titapun,1,2 Anchalee Techasen,2,3 Prakasit Sa-Ngiamwibool,2,4 Paiboon Sithithaworn,2,5 Vor Luvira,1,2 Tharatip Srisuk,1,2 Apiwat Jareanrat,1,2 Hasaya Dokduang,2,6 Watcharin Loilome,2,6 Bandit Thinkhamrop,2,7 Narong Khuntikeo1,2 1Department of ...
Titapun A, Techasen A, Sa-Ngiamwibool P, Sithithaworn P, Luvira V, Srisuk T, Jareanrat A, Dokduang H, Loilome W, Thinkhamrop B, Khuntikeo N   +10 more
doaj  

The Evolving Role of FGFR2 Inhibitors in Intrahepatic Cholangiocarcinoma: From Molecular Biology to Clinical Targeting

Cancer Management and Research, 2021
Massimiliano Salati,1,2 Francesco Caputo,1 Cinzia Baldessari,1 Pietro Carotenuto,3 Marco Messina,4 Stefania Caramaschi,5 Massimo Dominici,1 Luca Reggiani Bonetti5 1Department of Oncology and Hematology, University Hospital of Modena, Modena, Italy; 2PhD ...
Salati M, Caputo F, Baldessari C, Carotenuto P, Messina M, Caramaschi S, Dominici M, Bonetti LR   +7 more
doaj  

Subcellular localization of fibroblast growth factor receptor type 2 and correlation with CTNNB1 genotype in adrenocortical carcinoma

BMC Research Notes, 2020
Objective Fibroblast growth factor receptor (FGFR) 2 regulates the development of the adrenal gland in mice. In addition, FGFR2-mediated signalling has been shown to prevent apoptosis and to enhance proliferation in adrenocortical precursor cells.
Matthias Haase, Anne Thiel, Ute I. Scholl, Hany Ashmawy, Matthias Schott, Margret Ehlers   +5 more
doaj   +1 more source

Functional Distinctions of Endometrial Cancer-Associated Mutations in the Fibroblast Growth Factor Receptor 2 Gene

Cells, 2023
Functional analysis of somatic mutations in tumorigenesis facilitates the development and optimization of personalized therapy for cancer patients. The fibroblast growth factor receptor 2 (FGFR2) gene is frequently mutated in endometrial cancer (EC), but
Garima Dixit, Benjamin A. Pappas, Gourav Bhardwaj, Willow Schanz, Thorsten Maretzky   +4 more
doaj   +1 more source

Discovery of lirafugratinib (RLY-4008), a highly selective irreversible small-molecule inhibitor of FGFR2

Proceedings of the National Academy of Sciences of the United States of America
Significance Existing targeted therapies for solid tumors harboring FGFR2 alterations include pan-FGFR inhibitors, which often cannot be dosed to maximum efficacy due to FGFR1- and FGFR4-mediated toxicities.
Heike Schönherr, P. Ayaz, Alexander M Taylor, Jessica B Casaletto, B. B. Touré, D. Moustakas, Brandi M Hudson, Roberto Valverde, Songping Zhao, Patrick J O'Hearn, Lindsey Foster, Dina A Sharon, Sam Garfinkle, Fabrizio Giordanetto, André Lescarbeau, Ravi Kurukulasuriya, Nastaran Gerami-Moayed, Dejan Maglic, Kamil Bruderek, Gaauri Naik, Hakan Gunaydin, Mary M Mader, A. Boezio, Thomas H McLean, Rongfeng Chen, Yanxia Wang, David E. Shaw, Jim Watters, Donald A Bergstrom   +28 more
semanticscholar   +1 more source

Clinical application of a double-modified sulfated bacterial cellulose scaffold material loaded with FGFR2-modified adipose-derived stem cells in urethral reconstruction

Stem cell research & therapeutics, 2022
Urethral stricture and reconstruction are one of the thorny difficult problems in the field of urology. The continuous development of tissue engineering and biomaterials has given new therapeutic thinking to this problem.
Zhenpeng Zhu, Jiayu Yang, X. Ji, Zicheng Wang, Cheng-xiang Dai, Su-ke Li, Xuesong Li, Yajie Xie, Yudong Zheng, Jian Lin, Liqun Zhou   +10 more
semanticscholar   +1 more source

Cancer-associated fibroblasts secrete FGF5 to inhibit ferroptosis to decrease cisplatin sensitivity in nasopharyngeal carcinoma through binding to FGFR2

Cell Death and Disease
Cisplatin (DDP)-based chemoradiotherapy is one of the standard treatments for nasopharyngeal carcinoma (NPC). However, the sensitivity and side effects of DDP to patients remain major obstacles for NPC treatment.
Feng Liu, Ling Tang, Huai Liu, Yanzhu Chen, Tengfei Xiao, Wan-Yi Gu, Hongmin Yang, Hui Wang, Pan Chen   +8 more
semanticscholar   +1 more source